Integration of HiBiT into enteroviruses: A universal tool for advancing enterovirus virology research

Rui Yu; Xiaohong Li; Peng Zhang; Minghao Xu; Jitong Zhao; Jingjing Yan; Chenli Qiu; Jiayi Shu; Shuo Zhang; Miaomiao Kang; Xiaoyan Zhang; Jianqing Xu; Shuye Zhang

doi:10.1016/j.virs.2024.03.004

June 2024

Citation: Rui Yu, Xiaohong Li, Peng Zhang, Minghao Xu, Jitong Zhao, Jingjing Yan, Chenli Qiu, Jiayi Shu, Shuo Zhang, Miaomiao Kang, Xiaoyan Zhang, Jianqing Xu, Shuye Zhang. Integration of HiBiT into enteroviruses: A universal tool for advancing enterovirus virology research .VIROLOGICA SINICA, 2024, 39(3) : 422-433. http://dx.doi.org/10.1016/j.virs.2024.03.004

Integration of HiBiT into enteroviruses: A universal tool for advancing enterovirus virology research

Rui Yu ^a ,
Xiaohong Li ^a ,
Peng Zhang ^c ,
Minghao Xu ^d ,
Jitong Zhao ^d ,
Jingjing Yan ^g ,
Chenli Qiu ^b,e ,
Jiayi Shu ^f ,
Shuo Zhang ^b ,
Miaomiao Kang ^b ,
Xiaoyan Zhang ^{b
,,} ,
Jianqing Xu ^{b
,,} ,
Shuye Zhang ^{a,b
,,}

a. School of Medicine, Shanghai University, Shanghai, 200444, China;
b. Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China;
c. Guangzhou Institutes of Biomedicine and Health, The Chinese Academy of Sciences, Guangzhou, 510530, China;
d. Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China;
e. Shanghai Geriatric Medical Center, Shanghai, 201104, China;
f. Clinical Center for Biotherapy, Zhongshan Hospital/Zhongshan Hospital (Xiamen), Fudan University, 361015, China;
g. Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China

Corresponding author: Xiaoyan Zhang, zhangxiaoyan@fudan.edu.cn
Jianqing Xu, xujianqing@fudan.edu.cn
Shuye Zhang, shuye_zhang@fudan.edu.cn
Received Date: 22 November 2023
Accepted Date: 11 March 2024
Available online: 16 March 2024

Abstract

The utilization of enteroviruses engineered with reporter genes serves as a valuable tool for advancing our understanding of enterovirus biology and its applications, enabling the development of effective therapeutic and preventive strategies. In this study, our initial attempts to introduce a NanoLuc luciferase (NLuc) reporter gene into recombinant enteroviruses were unsuccessful in rescuing viable progenies. We hypothesized that the size of the inserted tag might be a determining factor in the rescue of the virus. Therefore, we inserted the 11-amino-acid HiBiT tag into the genomes of enterovirus A71 (EV-A71), coxsackievirus A10 (CVA10), coxsackievirus A7 (CVA7), coxsackievirus A16 (CVA16), namely EV-A71-HiBiT, CVA16-HiBiT, CVA10-HiBiT, CVA7-HiBiT, and observed that the HiBiT-tagged viruses exhibited remarkably high rescue efficiency. Notably, the HiBiT-tagged enteroviruses displayed comparable characteristics to the wild-type viruses. A direct comparison between CVA16-NLuc and CVA16-HiBiT recombinant viruses revealed that the tiny HiBiT insertion had minimal impact on virus infectivity and replication kinetics. Moreover, these HiBiT-tagged enteroviruses demonstrated high genetic stability in different cell lines over multiple passages. In addition, the HiBiT-tagged viruses were successfully tested in antiviral drug assays, and the sensitivity of the viruses to drugs was not affected by the HiBiT tag. Ultimately, our findings provide definitive evidence that the integration of HiBiT into enteroviruses presents a universal, convenient, and invaluable method for advancing research in the realm of enterovirus virology. Furthermore, HiBiT-tagged enteroviruses exhibit great potential for diverse applications, including the development of antivirals and the elucidation of viral infection mechanisms.
- Enterovirus
- , Infectious clones
- , Reporter genes
- , Luciferase
- , Drug screening

Electronic Supplementary Material

10.1016j.virs.2024.03.004-ESM.docx
References
1. Arnold, G.F., Resnick, D.A., Smith, A.D., Geisler, S.C., Holmes, A.K.,Arnold, E., 1996. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology, 39, 72-78.
2. Cao, J.M., Qu, M., Liu, H.T., Wan, X., Li, F., Hou, A., Zhou, Y., Sun, B., Cai, L.J., Su, W.H.,Jiang, C.L., 2020. Myristoylation of EV71 VP4 is essential for infectivity and interaction with membrane structure. Virol. Sin., 35, 599-613.
3. Chen, Y.K., Li, X.H., Wang, M., Li, Y., Fan, J., Yan, J.J., Zhang, S.Y., Lu, L.,Zou, P., 2023. A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection. Curr. Res. Microb. Sci., 5, 100203.
4. Chiu, W.Y., Lo, Y.H.,Yeh, T.C., 2016. Coxsackievirus associated hand, foot and mouth disease in an adult. QJM-an International Journal of Medicine, 109, 823-824.
5. Chou, A.H., Liu, C.C., Chang, J.Y., Jiang, R.N., Hsieh, Y.C., Tsao, A., Wu, C.L., Huang, J.L., Fung, C.P., Hsieh, S.M., Wang, Y.F., Wang, J.R., Hu, M.H., Chiang, J.R., Su, I.J.,Chong, P.C.S., 2013. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One, 8: e79783.
6. Chu, J.Q., Lee, Y.J., Park, J.N., Kim, S.M., Lee, K.N., Ko, Y.J., Lee, H.S., Cho, I.S., Kim, B.,Park, J.H., 2013. Construction of a bovine enterovirus-based vector expressing a foot-and-mouth disease virus epitope. J. Virol Methods, 189, 101-104.
7. Chua, K.B., Ng, Q., Meng, T.,Jia, Q., 2022. Development of stable, cold-adapted, temperature-sensitive/conditional lethal chimeric enterovirus A71 and coxsackievirus A16. Virol. Sin., 37, 769-773.
8. Deng, C.L., Li, X.D., Liu, S.Q., Xu, L.L., Ye, H.Q., Qin, C.F.,Zhang, B., 2015. Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone. Virol. Sin., 30, 269-276.
9. Gao, Q.Q., Yuan, S.L., Zhang, C., Wang, Y., Wang, Y.Z., He, G.M., Zhang, S.Y., Altmeyer, R.,Zou, G., 2015. Discovery of itraconazole with broad-spectrum, antienterovirus activity that targets nonstructural protein 3A. Antimicrob. Agents Chemother., 59, 2654-2665.
10. Gaspar, N., Zambito, G., Dautzenberg, I.J.C., Cramer, S.J., Hoeben, R.C., Lowik, C., Walker, J.R., Kirkland, T.A., Smith, T.P., Van Weerden, W.M., De Vrij, J.,Mezzanotte, L., 2020. NanoBiT system and hydrofurimazine for optimized detection of viral infection in mice-a novel in vivo imaging platform. Int. J. Mol. Sci., 21, 5863.
11. Hashem, S.M., Gad, M.K., Anwar, H.M., Saleh, N.M., Shamma, R.N.,Elsherif, N.I., 2023. Itraconazole-loaded ufasomes: evaluation, characterization, and anti-fungal activity against. Pharmaceutics, 15, 26.
12. Jubelt, B.,Lipton, H.L., 2014. Enterovirus/picornavirus infections. Handb. Clin. Neurol., 123, 379-416.
13. Kim, C., Kang, H., Kim, D.E., Song, J.H., Choi, M., Kang, M., Lee, K., Kim, H.S., Shin, J.S., Jeong, H., Jung, S., Han, S.B., Kim, J.H., Ko, H.J., Lee, C.K., Kim, M.,Cho, S., 2016. Antiviral activity of micafungin against enterovirus 71. Virol. J., 13, 99.
14. Kimmis, B.D., Downing, C.,Tyring, S., 2018. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis, 102, 353-356.
15. Liang, X.Y., Zhu, Q.C., Liang, J.Q., Liu, S.Y., Liu, D.X.,Fung, T.S., 2020. Development of HiBiT-tagged recombinant infectious bronchitis coronavirus for efficient and viral quantification. Front. Microbiol., 11, 2100.
16. Lyu, K., Wang, G.C., He, Y.L., Han, J.F., Ye, Q., Qin, C.F.,Chen, R., 2015. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J. Biol. Chem., 290, 3198-3208.
17. Miyakawa, K., Jeremiah, S.S., Ohtake, N., Matsunaga, S., Yamaoka, Y., Nishi, M., Morita, T., Saji, R., Nishii, M., Kimura, H., Hasegawa, H., Takeuchi, I.,Ryo, A., 2020. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. J. Mol. Cell Biol., 12, 987-990.
18. Nagashima, S., Primadharsini, P.P., Nishiyama, T., Takahashi, M., Murata, K.,Okamoto, H., 2023. Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an antiviral drug screening platform. J. Virol., 97, e0050823.
19. Ren, P.J., Zheng, Y.M., Wang, W.Q., Hong, L.P., Delpeyroux, F., Arenzana-Seisdedos, F.,Altmeyer, R., 2017. Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A. Sci. Rep., 7, 42902.
20. Ren, P.J., Zou, G., Bailly, B., Xu, S.S., Zeng, M., Chen, X.S., Shen, L., Zhang, Y., Guillon, P., Arenzana-Seisdedos, F., Buchy, P., Li, J., Von Itzstein, M., Li, Q.H.,Altmeyer, R., 2014. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg. Microbes Infect., 3: e62.
21. Rezaei, R., Surendran, A., Singaravelu, R., Jamieson, T.R., Taklifi, P., Poutou, J., Azad, T.,Ilkow, C.S., 2021. Detection of SARS-CoV-2 receptor-binding domain antibody using a HiBiT-based bioreporter. J. Vis. Exp., 174: e62488, https://doi.org/10.3791/62488.
22. Sarma, N., 2013. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian J. Dermatol. Venereol. Leprol., 79, 165-175.
23. Shang, B.D., Deng, C.L., Ye, H.G., Xu, W.B., Yuan, Z.M., Shi, P.Y.,Zhang, B., 2013. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antivir. Res., 97, 198-205.
24. Shribman, A.J.,Hanning, C.D., 1986. Hyperbaric bupivacaine and hyperbaric cinchocaine: a comparison of their use for spinal anaesthesia. Eur. J. Anaesthesiol., 3, 103-110.
25. Simmonds, P., Gorbalenya, A.E., Harvala, H., Hovi, T., Knowles, N.J., Lindberg, A.M., Oberste, M.S., Palmenberg, A.C., Reuter, G., Skern, T., Tapparel, C., Wolthers, K.C., Woo, P.C.Y.,Zell, R., 2020. Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch. Virol., 165, 793-797.
26. Sinclair, W.,Omar, M., 2023. Enterovirus. StatPearls. Treasure Island (FL).
27. Strating, J.R.P.M., Van Der Linden, L., Albulescu, L., Bigay, J., Arita, M., Delang, L., Leyssen, P., Van Der Schaar, H.M., Lanke, K.H.W., Thibaut, H.J., Ulferts, R., Drin, G., Schlinck, N., Wubbolts, R.W., Sever, N., Head, S.A., Liu, J.O., Beachy, P.A., De Matteis, M.A., Shair, M.D., Olkkonen, V.M., Neyts, J.,Van Kuppeveld, F.J.M., 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep., 10, 600-615.
28. Sumiyadorj, A., Murai, K., Shimakami, T., Kukroki, K., Nishikawa, T., Kakuya, M., Yamada, A., Wang, Y., Ishida, A., Shirasaki, T., Kawase, S., Li, Y.Y., Okada, H., Nio, K., Kawaguchi, K., Yamashita, T., Sakai, Y., Duger, D., Mizukoshi, E., Honda, M.,Kaneko, S., 2022. A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes. Hepatol. Commun., 6, 2441-2454.
29. Ulferts, R., De Boer, S.M., Van Der Linden, L., Bauer, L., Lyoo, H.R., Mate, M.J., Lichiere, J., Canard, B., Lelieveld, D., Omta, W., Egan, D., Coutard, B.,Van Kuppeveld, F.J.M., 2016. Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C. Antimicrob. Agents Chemother., 60, 2627-2638.
30. Van Der Schaar, H.M., Melia, C.E., Van Bruggen, J.a.C., Strating, J.R.P.M., Van Geenen, M.E.D., Koster, A.J., Barcena, M.,Van Kuppeveld, M., 2016. Illuminating the sites of enterovirus replication in living cells by using a split-GFP-tagged viral protein. mSphere, 1, e00104-e00116.
31. Wang, M., Yan, J., Zhu, L., Wang, M., Liu, L., Yu, R., Chen, M., Xun, J., Zhang, Y., Yi, Z.,Zhang, S., 2020. The establishment of infectious clone and single round infectious particles for coxsackievirus A10. Virol. Sin., 35, 426-435.
32. Xu, L.L., Shan, C., Deng, C.L., Li, X.D., Shang, B.D., Ye, H.Q., Liu, S.Q., Yuan, Z.M., Wang, Q.Y., Shi, P.Y.,Zhang, B., 2015. Development of a stable luciferase enterovirus 71 reporter virus. J. Virol. Methods, 219, 62-66.
33. Yu, R., Wang, M., Liu, L., Yan, J., Fan, J., Li, X., Kang, M., Xu, J., Zhang, X.,Zhang, S., 2022. The development and characterization of a stable Coxsackievirus A16 infectious clone with Nanoluc reporter gene. Front. Microbiol., 13, 1101850.
34. Yun, S.I., Song, B.H., Woolley, M.E., Frank, J.C., Julander, J.G.,Lee, Y.M., 2020. Development, characterization, and application of two reporter-expressing recombinant Zika viruses. Viruses-Basel, 12, 572.
35. Zhang, C., Zhang, G., Zhang, Y., Lin, X., Zhao, X., Cui, Q., Rong, L.,Du, R., 2023. Development of an HiBiT-tagged reporter H3N2 influenza A virus and its utility as an antiviral screening platform. J. Med. Virol., 95, e28345.
36. Zhou, Y., Li, J.X., Jin, P.F., Wang, Y.X.,Zhu, F.C., 2016. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev. Vaccines, 15, 803-813.
37. Zhu, F.C., Meng, F.Y., Li, J.X., Li, X.L., Mao, Q.Y., Tao, H., Zhang, Y.T., Yao, X., Chu, K., Chen, Q.H., Hu, Y.M., Wu, X., Liu, P., Zhu, L.Y., Gao, F., Jin, H., Chen, Y.J., Dong, Y.Y., Liang, Y.C., Shi, N.M., Ge, H.M., Liu, L., Chen, S.G., Ai, X., Zhang, Z.Y., Ji, Y.G., Luo, F.J., Chen, X.Q., Zhang, Y., Zhu, L.W., Liang, Z.L.,Shen, X.L., 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 381, 2024-2032.
Proportional views